BACKGROUND Breast cancer is one of the most common malignant tumors in women worldwide and poses a severe threat to their health.Therefore,this study examined patients who underwent breast cancer surgery,analyzed hosp...BACKGROUND Breast cancer is one of the most common malignant tumors in women worldwide and poses a severe threat to their health.Therefore,this study examined patients who underwent breast cancer surgery,analyzed hospitalization costs and structure,and explored the impact of China Healthcare Security Diagnosis Related Groups(CHS-DRG)management on patient costs.It aimed to provide medical institutions with ways to reduce costs,optimize cost structures,reduce patient burden,and improve service efficiency.AIM To study the CHS-DRG payment system’s impact on breast cancer surgery costs.METHODS Using the CHS-DRG(version 1.1)grouping criteria,4073 patients,who underwent the radical resection of breast malignant tumors from January to December 2023,were included in the JA29 group;1028 patients were part of the CHS-DRG payment system,unlike the rest.Through an independent sample t-test,the length of hospital stay as well as total hospitalization,medicine and consumables,medical,nursing,medical technology,and management expenses were compared.Pearson’s correlation coefficient was used to test the cost correlation.RESULTS In terms of hospitalization expenses,patients in the CHS-DRG payment group had lower medical,nursing,and management expenses than those in the diagnosis-related group(DRG)non-payment group.For patients in the DRG payment group,the factors affecting the total hospitalization cost,in descending order of relevance,were medicine and consumable costs,consumable costs,medicine costs,medical costs,medical technology costs,management costs,nursing costs,and length of hospital stay.For patients in the DRG nonpayment group,the factors affecting the total hospitalization expenses in descending order of relevance were medicines and consumable expenses,consumable expenses,medical technology expenses,the cost of medicines,medical expenses,nursing expenses,length of hospital stay,and management expenses.CONCLUSION The CHS-DRG system can help control and reduce unnecessary medical expenses by controlling medicine costs,medical consumable costs,and the length of hospital stay while ensuring medical safety.展开更多
目的研究按疾病诊断相关分组(diagnosis related groups,DRGs)付费实施对血液病患者住院费用的影响,为医院进行医保精细化管理提供决策依据。方法从天津市某三甲医院医院信息系统(hospital information system,HIS)中选取2021年10月—2...目的研究按疾病诊断相关分组(diagnosis related groups,DRGs)付费实施对血液病患者住院费用的影响,为医院进行医保精细化管理提供决策依据。方法从天津市某三甲医院医院信息系统(hospital information system,HIS)中选取2021年10月—2022年3月和2022年10月—2023年3月共21448例患者的病历资料,经过倾向得分匹配法进行匹配,筛选出8134例血液病患者,再利用双重差分法分析DRG付费对血液病患者住院费用的影响。结果实施DRGs付费后,血液病患者的检查费的中位数从6306.50元降至5038.50元,自付费用中位数从7607.17元降至6562.08元,材料费的中位数从305.70元降至286.88元。本研究进一步通过DID分析消除潜在混杂因素的影响,发现自付费用仍下降(P<0.05)。结论DRGs控费初见成效,有效降低了血液病患者的个人负担,医院应持续关注DRGs的长期效果。展开更多
目的:探讨在(疾病)诊断相关分类(diagnosis related groups,DRGs)形势下,腹腔镜结直肠癌经自然腔道取标本(NOSES)手术方式改进及其可行性。方法:回顾性分析安阳市肿瘤医院2019年2月至2021年2月实施DRGs的42例改进后的腹腔镜结直肠癌NOSE...目的:探讨在(疾病)诊断相关分类(diagnosis related groups,DRGs)形势下,腹腔镜结直肠癌经自然腔道取标本(NOSES)手术方式改进及其可行性。方法:回顾性分析安阳市肿瘤医院2019年2月至2021年2月实施DRGs的42例改进后的腹腔镜结直肠癌NOSES术,并与同期进行常规腹腔镜结直肠癌手术的238例患者在费用、治疗结果、并发症等方面相比较。结果:NOSES改进组42例患者DRGs控费成功率为95.2%(40/42),与常规腹腔镜组在DRGs费用及近期并发症发生率方面无显著性差异(P>0.05)。结论:腹腔镜结直肠癌NOSES改进手术可以达到DRGs费用标准,手术安全可靠,应用双7号丝线代替部分直线切割闭合器是可行的。展开更多
基金Research Center for Capital Health Management and Policy,No.2024JD09.
文摘BACKGROUND Breast cancer is one of the most common malignant tumors in women worldwide and poses a severe threat to their health.Therefore,this study examined patients who underwent breast cancer surgery,analyzed hospitalization costs and structure,and explored the impact of China Healthcare Security Diagnosis Related Groups(CHS-DRG)management on patient costs.It aimed to provide medical institutions with ways to reduce costs,optimize cost structures,reduce patient burden,and improve service efficiency.AIM To study the CHS-DRG payment system’s impact on breast cancer surgery costs.METHODS Using the CHS-DRG(version 1.1)grouping criteria,4073 patients,who underwent the radical resection of breast malignant tumors from January to December 2023,were included in the JA29 group;1028 patients were part of the CHS-DRG payment system,unlike the rest.Through an independent sample t-test,the length of hospital stay as well as total hospitalization,medicine and consumables,medical,nursing,medical technology,and management expenses were compared.Pearson’s correlation coefficient was used to test the cost correlation.RESULTS In terms of hospitalization expenses,patients in the CHS-DRG payment group had lower medical,nursing,and management expenses than those in the diagnosis-related group(DRG)non-payment group.For patients in the DRG payment group,the factors affecting the total hospitalization cost,in descending order of relevance,were medicine and consumable costs,consumable costs,medicine costs,medical costs,medical technology costs,management costs,nursing costs,and length of hospital stay.For patients in the DRG nonpayment group,the factors affecting the total hospitalization expenses in descending order of relevance were medicines and consumable expenses,consumable expenses,medical technology expenses,the cost of medicines,medical expenses,nursing expenses,length of hospital stay,and management expenses.CONCLUSION The CHS-DRG system can help control and reduce unnecessary medical expenses by controlling medicine costs,medical consumable costs,and the length of hospital stay while ensuring medical safety.
文摘目的研究按疾病诊断相关分组(diagnosis related groups,DRGs)付费实施对血液病患者住院费用的影响,为医院进行医保精细化管理提供决策依据。方法从天津市某三甲医院医院信息系统(hospital information system,HIS)中选取2021年10月—2022年3月和2022年10月—2023年3月共21448例患者的病历资料,经过倾向得分匹配法进行匹配,筛选出8134例血液病患者,再利用双重差分法分析DRG付费对血液病患者住院费用的影响。结果实施DRGs付费后,血液病患者的检查费的中位数从6306.50元降至5038.50元,自付费用中位数从7607.17元降至6562.08元,材料费的中位数从305.70元降至286.88元。本研究进一步通过DID分析消除潜在混杂因素的影响,发现自付费用仍下降(P<0.05)。结论DRGs控费初见成效,有效降低了血液病患者的个人负担,医院应持续关注DRGs的长期效果。
文摘目的:探讨在(疾病)诊断相关分类(diagnosis related groups,DRGs)形势下,腹腔镜结直肠癌经自然腔道取标本(NOSES)手术方式改进及其可行性。方法:回顾性分析安阳市肿瘤医院2019年2月至2021年2月实施DRGs的42例改进后的腹腔镜结直肠癌NOSES术,并与同期进行常规腹腔镜结直肠癌手术的238例患者在费用、治疗结果、并发症等方面相比较。结果:NOSES改进组42例患者DRGs控费成功率为95.2%(40/42),与常规腹腔镜组在DRGs费用及近期并发症发生率方面无显著性差异(P>0.05)。结论:腹腔镜结直肠癌NOSES改进手术可以达到DRGs费用标准,手术安全可靠,应用双7号丝线代替部分直线切割闭合器是可行的。
